Steven Yeh, MD, professor of ophthalmology at the Truhlsen Eye Institute at the University of Nebraska Medical Center, discusses the length of Xipere's treatment benefits and potential learning curves regarding its suprachoroidal delivery mechanism.
Steven Yeh, MD, professor of ophthalmology at the Truhlsen Eye Institute at the University of Nebraska Medical Center, discusses the length of Xipere's treatment benefits and potential learning curves regarding its suprachoroidal delivery mechanism.
Transcript
What did the PEACHTREE study find about how long Xipere's treatment benefits last?
Following the PEACHTREE study, patients who had successfully completed the PEACHTREE trial did not need other rescue therapies—namely, other medications that were administered to patients who had flare ups of their inflammation—were subsequently enrolled into the MAGNOLIA study, which was an extension study that evaluated the durability of the medication in the suprachoroidal space. What we found was that 50% of individuals who did not need rescue therapy did not need additional rescue therapy at the 48-week time point, showing that 50% of patients showed durability signals out to nearly a year at the end of this trial.
Are there any limitations or potential disadvantages of this new method?
With this novel method of drug delivery, it's important to remember that it's a nuanced technique that's different than intravitreal injections, which is the most commonly used method of delivery into the eye. For this reason, investigators and clinicians who perform this procedure really need to go up the learning curve to understand how suprachoroidal delivery is achieved.
When physicians administer the medication with the microinjector, it's important to position the needle perpendicular to the sclera. As the medication goes into the suprachoroidal space, clinicians will feel a loss of resistance, knowing that they're in the right location. Once they achieve this learning curve, they'll be able to successfully deliver the medication for patients with noninfectious uveitis.
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Joanne Mizell: Lifestyle Modification Programs Take Holistic Aim at Metabolic Disease
May 1st 2024Joanne Mizell shares insurer strategies in addressing the escalating rates of metabolic diseases, highlighting the importance of holistic treatment methods like lifestyle modification programs, which integrate nutrition, physical activity, and community engagement.
Read More